Comparative Pharmacology
Head-to-head clinical analysis: ACTIVELLA versus FEMINONE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ACTIVELLA versus FEMINONE.
ACTIVELLA vs FEMINONE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination of estradiol, an estrogen, and norethindrone acetate, a progestin. Estrogens act by binding to nuclear estrogen receptors (ERα and ERβ), which then interact with estrogen response elements on DNA, leading to changes in gene expression that regulate growth, differentiation, and function of female reproductive tissues and other tissues. Norethindrone acetate is a progestin that induces secretory changes in the endometrium, reducing the risk of endometrial hyperplasia and carcinoma associated with unopposed estrogen therapy.
FEMINONE (progesterone) is a steroid hormone that binds to the progesterone receptor, modulating gene expression in target tissues. It transforms the endometrium from proliferative to secretory phase, reduces endometrial hyperplasia risk, and suppresses gonadotropin release via negative feedback.
One tablet (1 mg estradiol + 0.5 mg norethindrone acetate) orally once daily, continuously.
0.625 mg orally once daily
None Documented
None Documented
Estradiol has a terminal half-life of approximately 12–14 hours following transdermal administration. Norethindrone has a terminal half-life of approximately 8–10 hours. The combined product achieves steady-state within 3–5 days.
Terminal elimination half-life is approximately 7-8 hours (range 5-12 h); clinical significance: steady-state reaches after ~2-3 days, necessitates daily dosing for contraceptive efficacy.
Estradiol is primarily excreted in urine (∼50%) as glucuronide and sulfate conjugates, with ∼30% excreted in feces via biliary elimination. Norethindrone is excreted mainly in urine (∼60%) as metabolites, with ∼40% in feces.
Feminone (norethindrone) is primarily excreted in urine (approximately 70-80% as metabolites, with <5% as unchanged drug) and feces (20-30%).
Category C
Category C
Estrogen/Progestin Combination
Estrogen